CXCL1/8-CXCR1/2 Chemokine-Axis Matching CAR-T Development Service

Creative Biolabs provides a CXCL1/8–CXCR1/2 Chemokine-Axis Matching CAR-T Development Service for Solid Tumor Targeting, designed to overcome poor CAR-T infiltration and functional exhaustion within hostile tumor microenvironments. Through innovative chemokine receptor engineering and targeted homing strategies, our platform reprograms CAR-T cells to navigate CXCL1/8-rich regions, effectively converting immunosuppressive signals into precise trafficking cues.

Introduction

The CAR T-cell therapy in solid tumors is critically hampered by the dense, immunosuppressive TME. A major contributing factor is the inability of CAR-T cells to efficiently infiltrate the tumor mass. The TME frequently overexpresses CXCL1 and CXCL8, which are strong chemoattractants for immunosuppressive cells and are linked to angiogenesis and poor prognosis. By incorporating the respective receptor, CXCR1 or CXCR2, into the CAR construct, T cells are re-engineered to follow this highly expressed chemokine signal.

Fig.1 The complex network of the CXCL8-CXCR1/2 axis in the TME.^1,3

Creative Biolabs' CXCL1/8-CXCR1/2 Chemokine-Axis Matching

Solid tumors create dense, immunosuppressive microenvironments often rich in pro-tumorigenic chemokines like CXCL1 and CXCL8. Conventional CAR-T cells, lacking the matching receptor, are effectively blocked from reaching the tumor core. Our service directly addresses this fundamental limitation by genetically modifying your T cells to express the cognate receptor (CXCR1 or CXCR2) specific to the abundant TME ligands (CXCL1/8). This simple yet profound modification transforms a barrier into a highway, significantly increasing the intra-tumoral accumulation and persistence of your engineered cell product.

• Enhanced Homing Capacity: We deliver CAR-T constructs scientifically proven to migrate aggressively toward CXCL1/8 gradients, ensuring superior tumor penetration compared to unmodified counterparts.
• Reduced Functional Exhaustion: By improving initial T-cell trafficking and concentration, we reduce the prolonged peripheral circulation time, limiting systemic exposure and potentially minimizing off-target effects.
• Validated Solid Tumor Efficacy: Our resulting CAR-T cells are validated in advanced ex vivo TME models for enhanced cytotoxic capacity and sustained functionality under hypoxic and nutrient-deprived conditions.

Discover How We Can Help - Request a Consultation.

Platform Technologies for Chemokine Axis Analysis

Our service is built upon a robust foundation of cutting-edge cell engineering and functional validation platforms designed specifically for next-generation CAR-T systems. We utilize an integrated approach to ensure optimal receptor selection, expression, and functional validation.

Work Process

The required starting materials include target antigen information with expression patterns, T-cell source material from leukapheresis or PBMCs, and tumor microenvironment data specifying CXCL1/8 concentration ranges.

Core Benefits

• TME Intelligence: Use proprietary TME data to select CXCR1 or CXCR2, matching the homing signal to your tumor's chemokine profile.
• Integrated Validation: Chemotaxis assays provide precise, quantitative migration data for functional CAR-T evaluation.
• Manufacturing Excellence: Scalable protocols preserve T-cell memory phenotype, supporting long-term in vivo persistence and efficacy.

Data Support

This research tackles the challenge of using CAR-T cell therapy for solid tumors, which often resist treatment due to a hostile microenvironment and poor T-cell infiltration. The authors developed a novel strategy by engineering CAR-T cells to express receptors for IL-8, a cytokine released by tumors. This modification significantly improved the cells' ability to migrate into and persist within tumors, leading to complete regression and lasting immunity in aggressive pre-clinical cancer models.

Fig.2 Construction and in vitro analysis of CXCR1 or CXCR2-modified CAR T cells.^2,3

FAQs

Partner with Us

Creative Biolabs is your trusted partner in overcoming the critical TME barriers facing CAR-T therapy for solid tumors. By utilizing our proprietary CXCL1/8-CXCR1/2 Chemokine-Axis Matching technology, you gain a strategic advantage in T-cell homing, persistence, and overall therapeutic efficacy. We provide fully characterized, research-ready CAR-T cells supported by detailed data packages and validated protocols to accelerate your journey toward the clinic. Ready to revolutionize your solid tumor CAR-T project? Contact our team to discuss your antigen, TME profile, and goals.

References

1. Han, Zhi-Jian et al. "Roles of the CXCL8-CXCR1/2 Axis in the Tumor Microenvironment and Immunotherapy." Molecules (Basel, Switzerland) vol. 27,1 137. 27 Dec. 2021. https://doi.org/10.3390/molecules27010137
2. Jin, Linchun et al. "CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors." Nature Communications vol. 10,1 4016. 5 Sep. 2019. https://doi.org/10.1038/s41467-019-11869-4
3. Distributed under Open Access License CC BY 4.0, without modification.